Drugs / PBF-680
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02208973 | May → Oct 2014 | asthma | Sant Pau Research Institute | Completed | No outcome recorded |
| Phase 1 | NCT01845181 | Apr → Aug 2013 | asthma | Sant Pau Research Institute | Completed | No outcome recorded |
| Phase 24 trials · 2 met primary | ||||||
| Phase 2 | NCT05262218 | Dec 2021 → Feb 2024 | chronic obstructive pulmonary disease | Palobiofarma SL | Completed | Met primary |
| Phase 2 | NCT03774290 | Jun 2018 → Feb 2020 | asthma | Palobiofarma SL | Completed | Met primary |
| Phase 2 | NCT02635945 | Apr 2016 → Sep 2019 | asthma | Palobiofarma SL | Completed | No outcome recorded |
| Phase 2 | NCT01939587 | Dec 2013 → Jul 2014 | asthma | Sant Pau Research Institute | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2024-09-09 | Palo Biofarma, S.L | Results PAMPLONA, SPAIN, SEPTEMBER 9th, 2024—Palobiofarma is pleased to announce today positive top-line results in a Phase 2 trial of the novel oral drug PBF-680 in patients with moderate-to-severe COPD. palobiofarma.com ↗
The clinical study met its primary endpoint, with PBF-680 10 mg once daily demonstrating a statistically significant reduction in blood eosinophil count (BEC) from Baseline to Week 4 compared to placebo when added to standard of care. |
| 2020-09-07 | Palo Biofarma, S.L | Results Positive clinical results of Palobiofarma´s adenosine A1 antagonist PBF-680 presented at the European Respiratory Society meeting. palobiofarma.com ↗
The study concluded that in mild-to-moderate asthmatics, PBF-680 abrogated the LAR, and reduced the EAR, FeNO, and, remarkably, blood eosinophils, with correct safety profile. |
| 2020-09-03 | Palo Biofarma, S.L | Results Palobiofarma announces positive results from the Phase II clinical trial evaluating the preliminary efficacy and safety of its adenosine A1 receptor antagonist PBF-680 in mild to moderate asthmatics patients. palobiofarma.com ↗
The results confirm a clinically and statistically significant improvement in trough FEV1 of asthmatic patients taking 10mg of PBF-680 for 14 days compared to placebo. |
All press releases naming this drug 4 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PBF-680 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05262218 ↗ |
| Action | Inhibit | “To evaluate the adenosine A1 receptor antagonism in blood samples of healthy volunteer caused by the PBF-680 administration” NCT01845181 ↗1“Adenosine A1 receptor antagonist” CHEMBL3545162 ↗ |
| Route | Oral | “PBF-680 will be administered as single oral ascending dose” NCT01845181 ↗ |
| Target | ADORA1 | “Adenosine A1 receptor antagonist” CHEMBL3545162 ↗ |